Key result
Invasive hemodynamic monitoring shows minimal complications in complex CHD across ages in limited case reports.
Why the study?
The increasing burden of heart failure in patients with complex congenital heart disease requires innovative management strategies, but published data on implanted invasive hemodynamic monitoring in this population are limited.
Implanted invasive hemodynamic monitoring is a promising tool for managing heart failure in patients with complex congenital heart disease, though current evidence is limited to case reports and series.
Limited case-report data warrant caution in complex CHD; leaves open prospective trials on outcomes.
As the number of patients with congenital heart disease (CHD) continues to increase, the burden of heart failure (HF) in this population requires innovative strategies to individualize management. Given the success of implanted invasive hemodynamic monitoring (IHM) with the CardioMEMS TM HF system in adults with acquired HF, this is often suggested for use in patients with CHD, though published data are limited to case reports and case series. Therefore, this review summarizes the available published reports on the use of IHM in patients with complex CHD, describes novel applications, and highlights future directions for study. In patients with CHD, IHM has been used across the lifespan, from age 3 years to adulthood, with minimal device-related complications reported. IHM uses include (1) prevention of HF hospitalizations; (2) reassessment of hemodynamics after titration of medical therapy without repeated cardiac catheterization; (3) serial monitoring of at-risk patients for pulmonary hypertension to optimize timing of heart transplant referral; (4) and hemodynamic assessment with exercise (5) or after ventricular assist device placement. IHM has the potential to reduce the number of cardiac catheterizations in anatomically complex patients and, in patients with Fontan circulation, IHM pressures may have prognostic implications. In conclusion, though further studies are needed, as patients with CHD age and HF is more prevalent, this tool may assist CHD physicians in caring for this complex patient population.
No takes yet. Share an insight, caveat, or question.
Marshall et al. (2024) conducted a review in Complex congenital heart disease and heart failure. Implanted invasive hemodynamic monitoring (IHM) was evaluated. Implanted invasive hemodynamic monitoring in patients with complex congenital heart disease has been used from age 3 to adulthood with minimal complications, though data are limited to case reports.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: